Skip to main content
SpringerLink
Log in

Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oxymetazoline 1% cream (Rhofade™) is a topical α1A-agonist approved to treat persistent facial erythema associated with rosacea in adults in the USA. It relieves the redness of affected skin by inducing vasoconstriction in the superficial skin vasculature. In clinical trials, application of oxymetazoline cream for up to 1 year was effective and generally well tolerated in rosacea patients with persistent erythema, with a low incidence of application-site reactions and rebound erythema.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs. 2014;74(13):1457–65.

    Article  PubMed  CAS  Google Scholar 

  2. Gold LM, Draelos ZD. New and emerging treatments for rosacea. Am J Clin Dermatol. 2015;16(6):457–61.

    Article  PubMed  Google Scholar 

  3. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne and Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234–40.

    PubMed  Google Scholar 

  4. Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam Physician. 2015;92(3):187–96.

    PubMed  Google Scholar 

  5. Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17(2):150–8.

    PubMed  Google Scholar 

  6. Zeichner JA, Eichenfield L, Feldman SR, et al. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018;11(2):47–52.

    PubMed  PubMed Central  Google Scholar 

  7. Rhofade™ (oxymetazoline hydrochloride) cream, for topical use: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ba1cc5b-4f7f-491b-a5af-a6a14fb5affd. Accessed 12 Nov 2018.

  8. Kuang AW, DuBois J, Attar M, et al. Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea. J Drugs Dermatol. 2018;17(2):213–20.

    PubMed  Google Scholar 

  9. Del Rosso JQ. Topical α-agonist therapy for persistent facial erythema of rosacea and the addition of oxmetazoline to the treatment armamentarium: where are we now? J Clin Aesthet Dermatol. 2017;10(7):28–32.

    PubMed  PubMed Central  Google Scholar 

  10. Del Rosso JQ. Management of cutaneous rosacea: emphasis on new medical therapies. Expert Opin Pharmacother. 2014;15(14):2029–38.

    Article  PubMed  Google Scholar 

  11. Piwnica D, Pathak A, Schafer G, et al. In vitro safety pharmacology profiling of topical α-adrenergic agonist treatments for erythema of rosacea. Drugs R D. 2018;18(1):87–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Hsia E, Tian M, Gil D. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. Exp Dermatol. 2018;27(7):763–8.

    Article  PubMed  CAS  Google Scholar 

  13. Mirvaso® (brimonidine) topical gel, 0.33%: US prescribing information. Fort Worth (TX): Galderma Laboratories; 2017.

  14. Tian M, Hsia E, Andrews-Jones L, et al. The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model [abstract no. 1251]. J Invest Dermatol. 2013;133(Suppl 1):S213.

    Google Scholar 

  15. Hsia E, Tian M, Santori E, et al. The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodilation and LL-37-induced skin inflammation [abstract no. 021]. J Invest Dermatol. 2012;132(Suppl. 1):S4.

    Google Scholar 

  16. DuBois J, Dover JS, Jones TM, et al. Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea. J Drugs Dermatol. 2018;17(3):308–16.

    PubMed  Google Scholar 

  17. Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17(1):97–105.

    PubMed  Google Scholar 

  18. Baumann L, Goldberg DJ, Stein-Gold L, et al. Pivotal trial of the efficacy and safey of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17(3):290–8.

    PubMed  Google Scholar 

  19. Stein-Gold L, Kircik LH, Draelos ZD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 17(11):1201–8.

  20. Tanghetti EA, Dover JS, Goldberg DJ, et al. Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1.0. J Drugs Dermatol. 2018;17(6):621–6.

    PubMed  CAS  Google Scholar 

  21. Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156–63.

    Article  PubMed  CAS  Google Scholar 

  22. Gold MH, Lebwohl M, Biesman BS, et al. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistant erythema of rosecea through 52 weeks of treatment [letter]. J Am Acad Dermatol. 79(3):e57–e59.

Download references

Acknowledgements

This manuscript was reviewed by: R.M. Hoover, Department of Pharmacy Practice and Administrative Sciences, Idaho State University, Pocatello, ID, USA; L.H. Kircik, Icahn School of Medicine at Mount Sinai, New York, NY, USA; F. Vilchez-Márquez, Department of Dermatology, Hospital de Guadix, Guadix, Spain. During the peer review process, the marketing-authorization holder of oxymetazoline 1% cream was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Kate McKeage & Katherine A. Lyseng-Williamson

Authors
  1. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McKeage, K., Lyseng-Williamson, K.A. Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA. Drugs Ther Perspect 35, 7–12 (2019). https://doi.org/10.1007/s40267-018-0592-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0592-1

Search

Navigation